Inside Precision Medicine October 22, 2024
Research led by teams in Lausanne, Switzerland has developed a chimeric antigen-receptor (CAR)-T cell therapy that can be switched on and off using readily available existing drugs.
CAR-T cell therapies are a type of cancer immunotherapy where T cells are engineered to better target the cancer cells of interest. These mostly involve a patient’s own cells, which are extracted, engineered and reintroduced to the body to target the patient’s cancer.
CAR-T cell therapies have been used successfully to treat advanced “liquid” cancers such as leukemia and lymphoma. Several are approved, but treatment of “solid” tumors, such as breast, lung, or prostate cancer, among others, with these therapies has proved challenging.
“CAR-T cells are already used today to treat a number...
Today's Sponsors
Today's Sponsor